Alatrofloxacin
![]() | |
| Clinical data | |
|---|---|
| AHFS/Drugs.com | Micromedex Detailed Consumer Information |
| MedlinePlus | a605016 |
| Pregnancy category |
|
| Routes of administration | Intravenous |
| ATC code | none |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | N/A |
| Protein binding | 76% (trovafloxacin) |
| Metabolism | Quickly hydrolyzed to trovafloxacin |
| Biological half-life | 9 to 12 hours (trovafloxacin) |
| Excretion | Fecal and renal (trovafloxacin) |
| Identifiers | |
| |
| CAS Number |
146961-76-4 |
| ChemSpider |
21243647 |
| UNII |
7QVV6I50DT |
| ChEMBL |
CHEMBL1201197 |
| Chemical and physical data | |
| Formula | C26H25F3N6O5 |
| Molar mass | 558.509 g/mol |
| 3D model (Jmol) | Interactive image |
| |
| |
| | |
Alatrofloxacin (Trovan IV) is a fluoroquinolone antibiotic developed by Pfizer, delivered as a mesylate salt.[1]
Trovafloxacin and alatrofloxacin were both withdrawn from the U.S. market in 2001.
See also
References
- ↑ "Center for Drug Evaluation and Research – Application Number: 020759/020760 – Chemistry Review(s)" (PDF). Food and Drug Administration. Retrieved 29 August 2014.
This article is issued from Wikipedia - version of the 4/2/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.
